CS-0003 is a first-in-class, Mucosal-Immune Modulator (MIM) therapeutic, that buffers the GI tract to prevent infections and reduce inflammation.
CS-0003 is a first-in-class Mucosal-Immune Modulator designed to stabilize the GI mucosal barrier,
suppress stress-induced bacterial virulence signaling, and support balanced mucosal-immune responses
upstream of inflammatory amplification.
GI surgery can destabilize the mucosal environment. Changes in barrier integrity and nutrient availability
may activate bacterial virulence pathways and increase infection risk.
CS-0003 is a gut-directed therapeutic designed to act locally at the GI mucosal interface and counter phosphate-responsive virulence signaling.
Lead Indication
Prevention of GI Surgical Site Infection in High-Risk GI Surgery. CS-0003 is not being developed to treat established GI-SSI.
Broader MIM Opportunity
Potential expansion opportunities include inflammatory bowel disease, anastomotic leak, recurrent C. difficile infection, sepsis, colon cancer recurrence, and chemotherapy-related GI toxicities.